BRUSSELS - Gilead Sciences said on Thursday that it had agreed to sell Europe up to 500,0000 courses of its antiviral drug remdesivir, as the continent shores up supplies of one of only two drugs approved to treat Covid-19 patients ahead of the winter.
New cases have been spiralling in Europe as the coming winter drives more people indoors, with cases soaring in neighbouring countries including Belgium, France and the Netherlands. EQUITABLE ACCESS The deal will help ease concerns about availability of the medicine after the company pledged most of its output to its home market over the summer months.
Sverige Senaste nytt, Sverige Rubriker
Similar News:Du kan också läsa nyheter som liknar den här som vi har samlat in från andra nyhetskällor.
Källa: BusinessTimes - 🏆 15. / 51 Läs mer »